Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078637 · ClinicalTrials.gov registry record · Phase 1
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00078637 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 37 participants.
The verdict
NCT00078637, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.
Interventions
- DRUG E7820
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078637
The ClinicalTrials.gov registry entry for NCT00078637 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7820 is the first listed.
NCT00078637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00078637 about?
NCT00078637 is a clinical study titled "Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma". This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.
What is the current status of trial NCT00078637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2004-01. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00078637?
The interventions under investigation include: E7820 (DRUG).
Who is sponsoring clinical trial NCT00078637?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.